You're asking about a chemical compound with a rather complex name: **1-(2,3-dimethyl-1-indolyl)-2-(4-methyl-1-piperidinyl)ethanone**.
Let's break it down:
* **1-(2,3-dimethyl-1-indolyl)**: This part indicates a specific indole derivative. Indoles are a class of organic compounds with a fused benzene and pyrrole ring system. The 2,3-dimethyl part means there are two methyl groups attached to the indole ring at positions 2 and 3.
* **2-(4-methyl-1-piperidinyl)**: This indicates a piperidine derivative, which is a six-membered ring containing a nitrogen atom. The 4-methyl indicates a methyl group attached to the piperidine ring at position 4.
* **ethanone**: This is the chemical name for a ketone functional group (C=O) connected to a two-carbon chain.
**Putting it all together**: This compound is a ketone with a complex structure containing both an indole and a piperidine ring.
**Importance in Research**:
Unfortunately, without further context, it's impossible to say why this specific compound is important for research. The importance likely depends on the specific research area. However, given its structure, it could be relevant to:
* **Drug discovery**: Indole and piperidine ring systems are commonly found in pharmaceuticals. This compound could be a potential lead compound for developing drugs targeting specific biological pathways.
* **Material science**: The compound's unique structure might give it interesting optical or electronic properties, making it useful for developing novel materials.
* **Organic chemistry**: It could be a valuable synthetic intermediate for creating other complex molecules.
**To get a better understanding of its significance, you would need to provide more context about the research field or study where this compound is being investigated.**
Let me know if you have more information, and I can help you understand its specific importance.
ID Source | ID |
---|---|
PubMed CID | 920008 |
CHEMBL ID | 1601589 |
CHEBI ID | 105359 |
Synonym |
---|
smr000146261 |
1-(2,3-dimethyl-indol-1-yl)-2-(4-methyl-piperidin-1-yl)-ethanone |
MLS000552746 , |
STK031176 |
1-(2,3-dimethyl-1h-indol-1-yl)-2-(4-methylpiperidin-1-yl)ethanone |
CHEBI:105359 |
1-(2,3-dimethylindol-1-yl)-2-(4-methylpiperidin-1-yl)ethanone |
AKOS002239087 |
HMS2286D16 |
CHEMBL1601589 |
1-(2,3-dimethyl-1h-indol-1-yl)-2-(4-methylpiperidin-1-yl)ethan-1-one |
1-(2,3-dimethyl-1-indolyl)-2-(4-methyl-1-piperidinyl)ethanone |
Q27183082 |
Z56802725 |
Class | Description |
---|---|
organonitrogen compound | Any heteroorganic entity containing at least one carbon-nitrogen bond. |
organooxygen compound | An organochalcogen compound containing at least one carbon-oxygen bond. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 35.4813 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
Smad3 | Homo sapiens (human) | Potency | 3.5481 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
PINK1 | Homo sapiens (human) | Potency | 39.8107 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
Parkin | Homo sapiens (human) | Potency | 39.8107 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 70.7946 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
serine-protein kinase ATM isoform a | Homo sapiens (human) | Potency | 39.8107 | 0.7079 | 25.1119 | 41.2351 | AID485349 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 12.5893 | 0.0079 | 8.2332 | 1,122.0200 | AID2546 |
neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 7.9433 | 0.0158 | 12.3113 | 615.5000 | AID1461 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |